ArticleFuture oncology (London, England)2025

ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC.

Guangmin Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.